Tero
Sign in
Companies›Biotech & health›NRG Therapeutics Ltd
Download
Company intelligence · Prepared from public filings

NRG Therapeutics Ltd

ACTIVENo. 11294505Incorporated 5 Apr 2018Stevenageneurodegeneration therapeutics
Register data as of 27 Aug 2026
10 filings read · view all sources ↓
Watch this company
Raised, filed rounds
£47.2m
Priced rounds
7
Peak step-up
1.3x
Peak implied valuation
£58.5m
Last allotment
Feb 2026
Exhibit 1

Implied valuation at each priced allotment, 2022 to 2026

Implied post-money, GBP · price per share beneath each point · from SH01 filings
£16.4m£32.8m£49.1m£65.5m2022202320242025202630 Jun 2022: £4.4m implied post-money at £3.97 per share1 Jul 2022: £8.8m implied post-money at £2.48 per share7 Jul 2022: £11.2m implied post-money at £2.48 per share1 May 2024: £26.0m implied post-money at £4.96 per share14 Jul 2025: £36.6m implied post-money at £4.96 per share27 Aug 2025: £38.5m implied post-money at £4.96 per share24 Feb 2026: £58.5m implied post-money at £4.96 per share£4.4m£3.97/sh£8.8m£2.48/sh£26.0m£4.96/sh£36.6m£4.96/sh£58.5m£4.96/shDown round: priced 38% below the prior round
Source: Companies House, forms SH01 filed by NRG Therapeutics Ltd; Tero analysis. Each point is one filed allotment; click any point to open the underlying filing.
Exhibit 2

Funding rounds, as filed

AllottedShare classPrice / shareRaisedImplied post-moneyStep vs priorSource
24 Feb 2026SERIES B£4.96£20.0m£58.5m· 1.0xSH01 ↗
27 Aug 2025SERIES B£4.96£1.9m£38.5m· 1.0xSH01 ↗
14 Jul 2025SERIES B£4.96£10.1m£36.6m· 1.0xSH01 ↗
1 May 2024SERIES A2£4.96£3.5m£26.0m▲ 2.0xSH01 ↗
7 Jul 2022SERIES A2 and ORDINARY£2.48£2.5m£11.2m· 1.0xSH01 ↗
1 Jul 2022SERIES A2£2.48£6.0m£8.8m▼ 0.63xSH01 ↗
30 Jun 2022SERIES A1, SERIES A2£3.97£3.2m£4.4mfirstSH01 ↗
Total, 7 priced rounds£47.2m
Source: Companies House filing history, company 11294505. Every row links to the filed document it was read from. Prices and share counts as filed; implied post-money is price per share times shares in issue after the allotment.
Similar companies on the register
Artios Pharma Limited
DNA damage response drug discovery
Grey Wolf Therapeutics Limited
immuno-oncology therapeutics
Draig Therapeutics Ltd
neuroscience therapeutics
Genomics Limited
genomic risk prediction
Methodology
Notes. Raised is the sum of shares allotted times price per share across priced allotments filed on form SH01. Peak step-up is the highest price per share divided by the first priced round. Implied post-money is price per share times shares in issue after the allotment: an approximation that ignores class rights and unexercised options. Allotments classified as option-scheme or nominal issues are excluded from the trajectory.
Primary documents
Every figure on this page is read from a document filed at Companies House and links to it. The full record is public: filing history of NRG Therapeutics Ltd at Companies House ↗. Tero retains an archived copy of each parsed filing. Information, not investment advice.